
Ilia I. Ouspenski
Examiner (ID: 3719, Phone: (571)272-2920 , Office: P/1644 )
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644 |
| Total Applications | 1597 |
| Issued Applications | 1033 |
| Pending Applications | 162 |
| Abandoned Applications | 435 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 12118836
[patent_doc_number] => 20180002422
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS'
[patent_app_type] => utility
[patent_app_number] => 15/533532
[patent_app_country] => US
[patent_app_date] => 2015-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 52969
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533532
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/533532 | Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents | Dec 6, 2015 | Issued |
Array
(
[id] => 10813745
[patent_doc_number] => 20160159905
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-09
[patent_title] => 'ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/958053
[patent_app_country] => US
[patent_app_date] => 2015-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 55062
[patent_no_of_claims] => 46
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14958053
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/958053 | Anti-PD-1 antibodies and methods of use thereof | Dec 2, 2015 | Issued |
Array
(
[id] => 11785020
[patent_doc_number] => 09394365
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2016-07-19
[patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of alzheimer\'s disease'
[patent_app_type] => utility
[patent_app_number] => 14/957065
[patent_app_country] => US
[patent_app_date] => 2015-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 56
[patent_no_of_words] => 21366
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14957065
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/957065 | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease | Dec 1, 2015 | Issued |
| 14/955843 | Antibodies, Uses & Methods | Nov 30, 2015 | Abandoned |
Array
(
[id] => 13106899
[patent_doc_number] => 10072082
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-11
[patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
[patent_app_type] => utility
[patent_app_number] => 14/950748
[patent_app_country] => US
[patent_app_date] => 2015-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 39748
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 222
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14950748
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/950748 | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling | Nov 23, 2015 | Issued |
Array
(
[id] => 13106897
[patent_doc_number] => 10072081
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-11
[patent_title] => Anti-CTLA4, anti-GLUT2 protein for the treatment of type 1 diabetes
[patent_app_type] => utility
[patent_app_number] => 14/943852
[patent_app_country] => US
[patent_app_date] => 2015-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 23111
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14943852
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/943852 | Anti-CTLA4, anti-GLUT2 protein for the treatment of type 1 diabetes | Nov 16, 2015 | Issued |
Array
(
[id] => 10822083
[patent_doc_number] => 20160168248
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-16
[patent_title] => 'Regulatory T Cell Mediator Proteins and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 14/940940
[patent_app_country] => US
[patent_app_date] => 2015-11-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 49326
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940940
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/940940 | Regulatory T cell mediator proteins and uses thereof | Nov 12, 2015 | Issued |
Array
(
[id] => 11205166
[patent_doc_number] => 09434785
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2016-09-06
[patent_title] => 'Anti-human OX40L antibodies and methods of treating graft versus host disease with the same'
[patent_app_type] => utility
[patent_app_number] => 14/935937
[patent_app_country] => US
[patent_app_date] => 2015-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 16
[patent_no_of_words] => 86443
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14935937
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/935937 | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same | Nov 8, 2015 | Issued |
Array
(
[id] => 11415271
[patent_doc_number] => 09562087
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-02-07
[patent_title] => 'High affinity PD-1 agents and methods of use'
[patent_app_type] => utility
[patent_app_number] => 14/931725
[patent_app_country] => US
[patent_app_date] => 2015-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 52
[patent_no_of_words] => 45235
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14931725
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/931725 | High affinity PD-1 agents and methods of use | Nov 2, 2015 | Issued |
Array
(
[id] => 15784939
[patent_doc_number] => 10626176
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-04-21
[patent_title] => Methods of treating conditions with antibodies that bind B7-H4
[patent_app_type] => utility
[patent_app_number] => 15/522061
[patent_app_country] => US
[patent_app_date] => 2015-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 26
[patent_no_of_words] => 30334
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 167
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15522061
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/522061 | Methods of treating conditions with antibodies that bind B7-H4 | Oct 29, 2015 | Issued |
Array
(
[id] => 10784192
[patent_doc_number] => 20160130348
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-05-12
[patent_title] => 'ANTIBODIES AND OTHER MOLECULES THAT BIND B7-H1 AND PD-1'
[patent_app_type] => utility
[patent_app_number] => 14/926732
[patent_app_country] => US
[patent_app_date] => 2015-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 40408
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14926732
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/926732 | ANTIBODIES AND OTHER MOLECULES THAT BIND B7-H1 AND PD-1 | Oct 28, 2015 | Abandoned |
Array
(
[id] => 10799187
[patent_doc_number] => 20160145344
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-05-26
[patent_title] => 'MURINE AND HUMAN INNATE LYMPHOID CELLS AND LUNG INFLAMMATION'
[patent_app_type] => utility
[patent_app_number] => 14/918277
[patent_app_country] => US
[patent_app_date] => 2015-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 12445
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14918277
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/918277 | MURINE AND HUMAN INNATE LYMPHOID CELLS AND LUNG INFLAMMATION | Oct 19, 2015 | Abandoned |
Array
(
[id] => 14667613
[patent_doc_number] => 10371702
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-08-06
[patent_title] => Detection and treatment of autoimmune disorders
[patent_app_type] => utility
[patent_app_number] => 14/874851
[patent_app_country] => US
[patent_app_date] => 2015-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 39
[patent_no_of_words] => 13964
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14874851
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/874851 | Detection and treatment of autoimmune disorders | Oct 4, 2015 | Issued |
Array
(
[id] => 10663639
[patent_doc_number] => 20160009784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-14
[patent_title] => 'Chimeric Receptors with 4-1BB Stimulatory Signaling Domain'
[patent_app_type] => utility
[patent_app_number] => 14/872947
[patent_app_country] => US
[patent_app_date] => 2015-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 21080
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14872947
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/872947 | Chimeric receptors with 4-1BB stimulatory signaling domain | Sep 30, 2015 | Issued |
Array
(
[id] => 11713662
[patent_doc_number] => 20170182161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-06-29
[patent_title] => 'Antigen Binding Proteins that Bind PD-L1'
[patent_app_type] => utility
[patent_app_number] => 14/864677
[patent_app_country] => US
[patent_app_date] => 2015-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 49442
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14864677
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/864677 | Antigen Binding Proteins that Bind PD-L1 | Sep 23, 2015 | Abandoned |
Array
(
[id] => 10656190
[patent_doc_number] => 20160002334
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-07
[patent_title] => 'BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS'
[patent_app_type] => utility
[patent_app_number] => 14/857402
[patent_app_country] => US
[patent_app_date] => 2015-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 39519
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14857402
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/857402 | Bi-specific antibodies against Tim-3 and PD-1 for immunotherapy in chronic immune conditions | Sep 16, 2015 | Issued |
Array
(
[id] => 10813751
[patent_doc_number] => 20160159910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-06-09
[patent_title] => 'ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES'
[patent_app_type] => utility
[patent_app_number] => 14/851003
[patent_app_country] => US
[patent_app_date] => 2015-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 42
[patent_no_of_words] => 77075
[patent_no_of_claims] => 100
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14851003
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/851003 | Anti-B7-H4 antibodies and immunoconjugates | Sep 10, 2015 | Issued |
Array
(
[id] => 13970485
[patent_doc_number] => 10214585
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-26
[patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
[patent_app_type] => utility
[patent_app_number] => 14/850794
[patent_app_country] => US
[patent_app_date] => 2015-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 56
[patent_no_of_words] => 21054
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850794
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/850794 | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS | Sep 9, 2015 | Issued |
Array
(
[id] => 13049263
[patent_doc_number] => 10046008
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-08-14
[patent_title] => Methods for treating chronic lymphocytic leukemia (CLL)
[patent_app_type] => utility
[patent_app_number] => 14/850542
[patent_app_country] => US
[patent_app_date] => 2015-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 26474
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 155
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850542
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/850542 | Methods for treating chronic lymphocytic leukemia (CLL) | Sep 9, 2015 | Issued |
Array
(
[id] => 11025162
[patent_doc_number] => 20160222117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-08-04
[patent_title] => 'NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 14/846457
[patent_app_country] => US
[patent_app_date] => 2015-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 66180
[patent_no_of_claims] => 85
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14846457
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/846457 | NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES | Sep 3, 2015 | Abandoned |